Clinical trials: APL
Kidney Cancer, Leukemia
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who…
- Conditions
- Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00066599
- Testing
- voriconazole
- Where
- 7 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Acquired Immunodeficiency Syndrome, HIV Infection
Phase I Study of APL 400-003, a Candidate HIV Vaccine, in HIV-Negative Volunteers
This is a randomized, double blind study of the safety and immunogenicity of APL 400-003, a plasmid DNA vaccine encoding the env and rev genes of HIV-1, in HIV-negative volunteers.
- Trial name
- NCT00001538
- Testing
- APL 400-003
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias
This is a Phase I study designed to determine the MTD and assess the toxicity associated with clofarabine followed by fractionated cyclophosphamide in patients > 1 year of age or < 21 years of age with relapsed or refractory…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Disorders, Acute Lymphocytic Leukemia
- Trial name
- POE07-01 (NCT00852709)
- Testing
- Clofarabine, Cyclophosphamide
- Where
- 7 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia
R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of R115777 in treating patients who have refractory or…
- Trial name
- NCT00004009
- Testing
- tipifarnib
- Where
- 3 sites in United States
- Sponsor
- University of Maryland, Baltimore
Leukemia
"AIDA" Protocol (LAP 0493)
The main purposes of the AIDA protocol are to test the role of intermittent maintenance therapy with ATRA, standard maintenance chemotherapy with methotrexate and 6-mercaptopurine of both in PCR negative patients at the end of…
- Trial name
- NCT01064557
- Testing
- all-trans retinoic acid (ATRA)
- Where
- 80 sites in Belgium, Germany and 3 more
- Volunteers
- 1,068 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Osteoarthritis
FCR or APL in LRTI - A Single Surgeon Randomized Controlled Trial
We are investigating the use of the flexor carpi radialis and abductor pollicis longus tendons in the use of trapeziectomy and ligament reconstruction with tendon interposition.
- Trial name
- NCT02540057
- Testing
- Flexor carpi radialis, Abductor pollicis longus
- Sponsor
- Nova Scotia Health Authority
Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia
BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid Leukemia
Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of BMS-214662 in treating patients who have acute leukemia, myelodysplastic…
- Conditions
- Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes
- Trial name
- NCT00006213
- Testing
- BMS-214662, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
CD33 Positive Acute Myelogenous Leukemia
Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy
An expanded access/compassionate use protocol that allows access to Mylotarg for relapsed/refractory AML CD33 positive patients in the USA. Contact: B1761026@iconplc.com
- Trial name
- AML (NCT02312037)
- Testing
- Antibody Drug Conjugate Chemotherapeutic
- Where
- 142 sites in United States
- Sponsor
- Pfizer
Acute Promyelocytic Leukemia (APL)
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
- Trial name
- NCT07597941
- Testing
- Lisaftoclax (APG-2575)
- Volunteers
- 20 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
This pilot phase I trial studies how well positron emission tomography (PET)/magnetic resonance imaging (MRI), fludeoxyglucose F-18 (18F-FDG) PET/computed tomography (CT), and whole body MRI work in finding extramedullary myeloid…
- Trial name
- NCT02390635
- Testing
- Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Acute Promyelocytic Leukemia
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
The safety and efficacy of combining NRX 195183 with arsenic trioxide in treating untreated APL will be assessed.
- Trial name
- NCT00670150
- Testing
- NRX 195183 (retinoid analogue), Arsenic Trioxide
- Where
- United States
- Sponsor
- University of Southern California
Cancer
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
RATIONALE: White blood cells from donors who have been exposed to cytomegalovirus may be able to help prevent this infection from occurring in patients who are undergoing bone marrow or peripheral stem cell transplantation.
- Trial name
- NCT00002673
- Testing
- infection prophylaxis and management
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD
In this multicenter, upfront randomized phase II trial, all patients receive quizartinib in combination with HAM (high-dose cytarabine, mitoxantrone) during salvage therapy.
- Trial name
- Q-HAM (NCT03989713)
- Testing
- MRD-triggered arm, Prophylactic Arm
- Where
- Germany
- Volunteers
- 11 people
- Sponsor
- Prof. Dr. Richard F Schlenk
Leukemia
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
The purpose of this study is to evaluate both the efficacy and toxicity of infusional arsenic trioxide in the treatment of patients with relapsed or refractory acute promyelocytic leukemia (APML).
- Trial name
- NCT00008697
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Washington University School of Medicine
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
This randomized phase I trial studies the side effects of vaccine therapy in preventing cytomegalovirus (CMV) infection in patients with hematological malignancies undergoing donor stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT01588015
- Testing
- tetanus-CMV fusion peptide vaccine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myelodysplastic Syndromes
Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with donor bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00004896
- Testing
- busulfan, cyclophosphamide, allogeneic bone marrow transplantation
- Where
- United States
- Sponsor
- Northwestern University
Leukemia, Myelodysplastic Syndromes
Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002547
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- United States
- Volunteers
- 280 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Promyelocytic Leukaemia
Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL
Acute Promyelocytic Leukaemia (APL) has been known as a type of cancer, which is of great significance to improve its eradication rate.
- Trial name
- RIF (NCT04175587)
- Testing
- Compound Realgar-Indigo Naturalis Formula Plus Retinoic Acid
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Thumb Osteoarthritis
Anatomical Evaluation of the APL Tendons in Thumb CMC Joint and Osteoarthritis
Certain ligaments in the human body are designed to be a static stabilizer and others to have a sensory function thus remains an unresolved issue.
- Trial name
- NCT05626192
- Testing
- Anatomical dissection and Immunohistochemical techniques
- Where
- 2 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau